Human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant (Merck & CO)

重组四价人乳头瘤病毒疫苗（默沙东）

Report date: 2026/02/10 20:00:22

Base Information

Drug NameHuman papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant (Merck & CO)
Drug Alias NameQuadrivalent human papillomavirus vaccine (Merck),,,四价人乳头瘤病毒疫苗(酿酒酵母)Human papillomavirus (HPV types 6, 11, 16, 18) recombinant vaccine (Merck & CO)Human papillomavirus (types 6 11 16 18) recombinant vaccine (Gardasil) - (Merck)Human papillomavirus vaccine quadrivalent (m) +[9] 
ClassificationVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II) +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsLupus Erythematosus, SystemicVaginal DiseasesUterine Cervical Incompetence +[14] 
Global Approved IndicationsUterine Cervical DysplasiaVulvar NeoplasmsVaginal Neoplasms +[6] 
Approved Indications in ChinaUterine Cervical NeoplasmsPapillomavirus InfectionsCondylomata Acuminata
Original Approved Country/TerritoryUnited States
Original Approved Date2006/06/08
Country/TerritoryCanadaUnited StatesTaiwan +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesThe University Of QueenslandCsl LtdMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme （Australia） Pty LtdMerck Sharp & Dohme CorpMerck Sharp & Dohme Bv +[9] 
Inactive CompaniesPreventive Oncology International IncWayne State UniversityH Lee Moffitt Cancer Center & Research Institute +[8] 
Active IndicationsUterine Cervical DysplasiaVulvar NeoplasmsVaginal Neoplasms +[8] 
Inactive IndicationsLupus Erythematosus, SystemicVaginal DiseasesUterine Cervical Incompetence +[6] 

Other Information

ATC CodeJ07BM01
Related LinksWikipediaKEGG